PMID- 27863801
OWN - NLM
STAT- MEDLINE
DCOM- 20171208
LR  - 20220318
IS  - 1872-7123 (Electronic)
IS  - 0165-1781 (Linking)
VI  - 246
DP  - 2016 Dec 30
TI  - Long-acting injectable antipsychotics for the prevention of relapse in patients 
      with recent-onset psychotic disorders: A systematic review and meta-analysis of 
      randomized controlled trials.
PG  - 750-755
LID - S0165-1781(16)30947-7 [pii]
LID - 10.1016/j.psychres.2016.10.053 [doi]
AB  - This meta-analysis of randomized controlled trials (RCTs) investigated the 
      advantages of long-acting injectable antipsychotics (LAI-APs) over oral 
      antipsychotics (OAPs) with regard to efficacy and safety for patients with 
      recent-onset psychotic disorders. Effect sizes and 95% confidence intervals 
      (95%CIs) were calculated. We identified five RCTs (1022 patients, mean study 
      duration=18+/-7.59 months) that compared LAI-APs (paliperidone or risperidone) with 
      OAPs. Pooled LAI-APs did not outperform OAPs in terms of the preventing of 
      relapse (N=3, n=875). However, there was significant heterogeneity (I(2)=76%), 
      with one study showing no superiority of LAI-APs over OAPs [Malla 2013: risk 
      ratio (RR)=1.83, 95%CI=0.70-4.77, n=77] and the other two studies showing LAI-APs 
      to be superior [Schreiner 2015: [RR=0.71, 95%CI=0.51-0.97, number needed to treat 
      (NNT)=-17, n=715, Subotnik 2015: RR=0.15, 95%CI=0.04-0.63, NNT=-4, n=83]. Pooling 
      the studies, there were no significant differences between LAI-APs and OAPs in 
      the improvement of Positive and Negative Syndrome Scale scores or in 
      discontinuation due to all-cause, adverse events (AEs), and death, but LAI-APs 
      outperformed OAPs in terms of discontinuation due to inefficacy (RR=0.34, 
      NNT=-50) and nonadherence (RR=0.30, NNT=-33). However, the LAI-APs were 
      associated with a higher incidence of at least one AE (RR=1.13) and tremor 
      (RR=2.38) compared with OAPs.
CI  - Copyright (c) 2016 Elsevier Ireland Ltd. All rights reserved.
FAU - Kishi, Taro
AU  - Kishi T
AD  - Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, 
      Aichi, Japan. Electronic address: tarok@fujita-hu.ac.jp.
FAU - Oya, Kazuto
AU  - Oya K
AD  - Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, 
      Aichi, Japan.
FAU - Iwata, Nakao
AU  - Iwata N
AD  - Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, 
      Aichi, Japan.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20161103
PL  - Ireland
TA  - Psychiatry Res
JT  - Psychiatry research
JID - 7911385
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Delayed-Action Preparations)
SB  - IM
MH  - Antipsychotic Agents/administration & dosage/*pharmacology
MH  - Delayed-Action Preparations/administration & dosage/*pharmacology
MH  - Humans
MH  - Psychotic Disorders/*drug therapy
MH  - Randomized Controlled Trials as Topic/*statistics & numerical data
MH  - Schizophrenia/*drug therapy
MH  - *Secondary Prevention
OTO - NOTNLM
OT  - *Long-acting injectable antipsychotics
OT  - *Meta-analysis
OT  - *Recent-onset psychotic disorders
OT  - *Relapse rate
OT  - *Systematic review
EDAT- 2016/11/20 06:00
MHDA- 2017/12/09 06:00
CRDT- 2016/11/20 06:00
PHST- 2016/05/31 00:00 [received]
PHST- 2016/08/29 00:00 [revised]
PHST- 2016/10/25 00:00 [accepted]
PHST- 2016/11/20 06:00 [pubmed]
PHST- 2017/12/09 06:00 [medline]
PHST- 2016/11/20 06:00 [entrez]
AID - S0165-1781(16)30947-7 [pii]
AID - 10.1016/j.psychres.2016.10.053 [doi]
PST - ppublish
SO  - Psychiatry Res. 2016 Dec 30;246:750-755. doi: 10.1016/j.psychres.2016.10.053. 
      Epub 2016 Nov 3.